A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung...
A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
B‐cell translocation gene 2 (BTG2) is a tumour suppressor protein known to be downregulated in several types of cancer. In this study, we investigated a potential role for BTG2 in early‐stage non‐small cell lung cancer (NSCLC) survival. We analysed BTG2 methylation data from 1230 early‐stage NSCLC patients from five international cohorts, as well a...
Alternative Titles
Full title
A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ca5629b0d0494cc8be05ad8f49820b5a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ca5629b0d0494cc8be05ad8f49820b5a
Other Identifiers
ISSN
1574-7891
E-ISSN
1878-0261
DOI
10.1002/1878-0261.12204
